Achieved primary endpoint demonstrating significant correlation between DetermaIO and two-year overall survival rate to atezolizumab in metastatic bladder cancer
DetermaIO identified additional immunotherapy responsive patients missed by commonly used biomarkers
Data supports potential utility of DetermaIO test across multiple solid tumors as predictor of response to Immune Checkpoint Inhibitor therapy in estimated $3 billion market in the United States
KOL Webinar discussing results to be held on April 19 at 11:30 AM EDT/8:30 AM PDT
https://finance.yahoo.com/news/oncocyte-presents-data-2021-american-173100664.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.